

SCHEDULE 1- Pediatric therapy-related myeloid neoplasm (tMN) Data Set Publication Policy

The primary purpose of the tMN study is to define the genomic alterations in therapy-related myeloid neoplasms (tMN) in children. These diseases occur after chemotherapy for an antecedent malignancy and can present as either a therapy-related myelodysplastic syndrome (tMDS) or therapy-related acute myeloid leukemia (tAML). The objective of the study was to define the somatic and germline alterations using WGS, WES and/or RNA-seq that drive tMN in children. The dataset is a mixture of paired tumor-normal samples or normal-only samples.

St. Jude Children's Research Hospital anticipates that data generated from this study will be used by other researchers (scientists who are employed by, or a student enrolled at or legitimately affiliated with, an academic, non-profit, or government institution) to develop new analytical methods, validate results, and identify additional genetic variations and alterations in the data.

Authors who use data from tMN must acknowledge this project using the following wording "This study makes use of data generated by the St. Jude Children's Research Hospital Pediatric therapy-related myeloid neoplasm (tMN) Study" and cite the relevant primary publication (<https://rdcu.be/cfaDF>). The publications can be found at the below website: <https://pecan.stjude.org/permalink/tMN>

Users should note that the St. Jude Children's Research Hospital bears no responsibility for the further analysis or interpretation of these data.